Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use

BACKGROUND: Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized study, romiplostim led to correction of platelet counts in 85...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Cy R., Ortiz, Jocelyn, Gilbert, Leah J., Yin, Shen, Mones, Jodi V., Parameswaran, Rekha, Mantha, Simon, Soff, Gerald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087952/
https://www.ncbi.nlm.nih.gov/pubmed/35582038
http://dx.doi.org/10.1002/rth2.12701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087952/
https://www.ncbi.nlm.nih.gov/pubmed/35582038
http://dx.doi.org/10.1002/rth2.12701

Ejemplares similares